Arrowhead Pharmaceuticals (NASDAQ:ARWR) Releases Earnings Results, Misses Expectations By $0 46 EPS themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Hypertriglyceridemia Clinical Trial Pipeline Insights | 20+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.
- Conference Call and Webcast Today, February 6, 2024, at 4:30 p.m. ETPASADENA, Calif. (BUSINESS WIRE) $arwr Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023. The Company is hosting a conference call today, February 6, 2024,.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Posts Earnings Results, Misses Expectations By $0 46 EPS theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) had its target price hoisted by analysts at Citigroup from $33.00 to $34.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. Citigroup’s price objective would suggest a potential upside of 8.35% from the stock’s previous close. […]